<DOC>
	<DOCNO>NCT02037529</DOCNO>
	<brief_summary>This two arm Phase III trial first second-line HER2 negative patient locally recurrent metastatic breast cancer . The primary endpoint overall survival ( OS ) , objective test superiority eribulin mesylate standard weekly paclitaxel . Patients randomized experimental control arm equal allocation ( 1:1 ) within stratum define prior adjuvant taxanes , hormone receptor status , line therapy . Subjects continue protocol direct therapy documentation disease progression , development unacceptable toxicity , withdrawal consent . Those discontinue study treatment without radiological progression follow repeat image study every 12 week . All subject follow death , withdrawal consent , study termination .</brief_summary>
	<brief_title>A Randomized Phase III Trial Eribulin Compared Standard Weekly Paclitaxel First- Second-Line Therapy Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologic confirmation invasive adenocarcinoma originate breast . 2 . Stage IV disease Stage IIIC disease ( use 7th edition AJCC criterion ) amenable local therapy . 3 . Radiographically measurable disease per RECIST guideline ( version 1.1 ) . 4 . Radiographic evidence disease progression . 5 . Documentation HER2 negative breast cancer time protocol registration . 6 . Known hormone receptor status time protocol registration . 7 . Prior systemic therapy per follow criterion : 1 . Patients must demonstrate resolution prior chemotherapy radiationrelated toxicity grade less equal 1 , include peripheral neuropathy , exception alopecia ( grade permissible ) . 2 . No one prior chemotherapy regimen advance metastatic breast cancer allow . Prior chemotherapy metastatic disease must complete great equal 14 day prior randomization . 3 . Prior treatment may include taxane adjuvant neoadjuvant setting , provide interval completion adjuvant therapy disease recurrence great 12 month . 4 . Any number prior hormonal therapy allow . 5 . Any number biologic therapy ( e.g. , bevacizumab ) immunotherapies allow absence coadministered chemotherapy must complete great equal 28 day prior randomization . 6 . Prior treatment investigational agent allow must complete great equal 28 day prior randomization . 8 . Prior local therapy per follow criterion : 1 . Minor surgical procedure must complete great equal 7 day prior randomization documentation adequate recovery associate complication grade less equal 1 . 2 . Major surgical procedure open biopsy must complete great equal 28 day prior randomization documentation adequate recovery associate complication grade less equal 1 . 3 . Prior radiotherapy must complete great equal 14 day prior randomization documentation adequate recovery associate toxicity grade less equal 1 . 9 . Concurrent supportive therapy per follow criterion : 1 . Treatment bisphosphonates denosumab allow recommend per standard care . 2 . Therapeutic anticoagulation allow patient stable dose warfarin low molecular weight heparin . 10 . ECOG performance status 0 , 1 , 2 . 11 . Life expectancy great 12 week . 12 . History brain metastasis per follow criterion : 1 . Patients history resect brain metastasis eligible asymptomatic stable MRI scan 3 consecutive month , include less equal 28 day study registration . 2 . Patients receive stereotactic radiosurgery whole brain radiation brain metastasis eligible asymptomatic stable MRI scan 3 consecutive month , include less equal 28 day study registration . 13 . Adequate organ function per blood work obtain less 7 day prior registration . 1 . Absolute neutrophil count great equal 1500/uL . 2 . Platelet count great equal 100,000/uL . 3 . Hemoglobin great equal 9 g/dL . 4 . Total bilirubin less equal 1.5 time upper limit normal ( ULN ) except unconjugated hyperbilirubinemia Gilbert 's syndrome . 5 . SGOT ( AST ) SGPT ( ALT ) less equal 3 x ULN except case liver metastasis , less equal 5 x ULN allow . 6 . Creatinine le equal 2.0 mg/dL creatinine clearance great 50 mL/min . 7 . QTc interval less equal 500 msec baseline electrocardiogram . 8 . Negative pregnancy test do less equal 72 hour prior registration woman childbearing potential . 14 . Ability complete questionnaire ( ) independently assistance . 15 . Willingness provide blood tissue sample correlative research purpose . 16 . Ability comprehend respond question use telephone keypad . 1 . Prior malignancy , carcinoma situ cervix nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat great equal 5 year previously , subsequent evidence recurrence , patient consider physician less 30 % risk relapse . 2 . Any following study involve investigational agent whose genotoxic , mutagenic , teratogenic effect develop fetus newborn unknown : 1 . Pregnant woman 2 . Nursing woman 3 . Men woman childbearing potential unwilling employ adequate contraception 3 . Presence serious nonhealing wound , ulcer , bone fracture . 4 . History CTCAE grade great equal 3 hypersensitivity paclitaxel Cremophor EL . 5 . Preexisting peripheral neuropathy grade great equal 2 registration . 6 . Significant cardiovascular impairment ( e.g. , New York Heart Association congestive heart failure grade II , unstable angina , myocardial infarction within past 6 month , serious cardiac arrhythmia ) . 7 . Subjects know positive HIV status . 8 . History stroke transient ischemic attack less equal 6 month prior registration . 9 . History uncontrolled seizure . 10 . Severe uncontrolled intercurrent illness/infection . 11 . Concurrent administration investigational agent consider potential efficacy treatment breast cancer . 12 . Prior exposure eribulin mesylate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally Recurrent</keyword>
</DOC>